scholarly journals Heart Failure and Aortic Stiffening in Patients with Preserved Ejection Fraction

2021 ◽  
Author(s):  
Özgür KUŞ ◽  
Barış ŞENSOY ◽  
Ahmet TEMIZHAN
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Preserved Ejection Fraction ◽  
Aortic Stiffening

Acute heart failure with preserved ejection fraction and long-term Readmisions

2008 ◽  
Vol 7 ◽  
pp. 62-63
Author(s):  
J NUNEZ ◽  
L MAINAR ◽  
G MINANA ◽  
R ROBLES ◽  
J SANCHIS ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Acute Heart Failure ◽  
Preserved Ejection Fraction

Thyroid function in heart failure with preserved ejection fraction (HFpEF) - evaluation of serum and myocardial thyroid hormones in an animal model of HFpEF

2017 ◽  
Author(s):  
Neves Joao Sergio ◽  
Catarina Vale ◽  
Joao Almeida-Coelho ◽  
Soledad Barez-Lopez ◽  
Obregon Maria Jesus ◽  
...  
Keyword(s):  
Heart Failure ◽  
Animal Model ◽  
Ejection Fraction ◽  
Thyroid Hormones ◽  
Thyroid Function ◽  
Preserved Ejection Fraction

Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Risk Stratification ◽  
Cardiac Fibrosis ◽  
The Elderly ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Large Populations ◽  
Galectin 3

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.

Sign in / Sign up

Export Citation Format

Share Document